Testing a rapid test for Candida auris
Part of Immune system & allergy, Infections clinical trials.
This trial is testing a rapid test to detect Candida auris, a hard-to-treat fungus. You can join if your doctor suspects you have this infection or you're being checked for it on your skin, and your lab sample is grown on specific plates or broths.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a suspected Candida auris infection (in blood or tissue) or be checked for skin colonization.
- If you have an infection, your sample must be grown on special lab plates used in the hospital (Sabouraud-dextrose and CHROMagar).
- If you are being checked on the skin, your sample must be grown on a salt-based broth (SSDB) and a standard liquid medium.
- No other limits – most people with a suspected Candida auris issue can join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a nasal antiseptic can reduce or prevent Candida auris infections in people who have had this germ before. It aims to find a simple way to lower the risk of future infection.
This study looks at patients in the intensive care unit who have a new infection with Candida (a type of fungus) despite taking strong antibiotics. It aims to better understand and diagnose these serious infections.
This trial tests whether reporting antibiotic sensitivity results in under 6 hours helps doctors choose the right β-lactam antibiotic faster for ICU patients with certain bloodstream infections. If you are in the ICU with a Gram-negative infection, your doctors will use a quick test to pick the best treatment.
This study tests a new rapid test (NuRapid-CRISPR) that quickly identifies the bacteria or fungus causing a serious blood infection in ICU patients. The goal is to help doctors start the right treatment faster and improve patient outcomes.
This trial tests a new rapid test and infection prevention plan for patients who may carry carbapenem-resistant bacteria (CPE) in the hospital. It aims to see if faster detection and better infection control can reduce the spread of these hard-to-treat germs.
This trial tests a new antifungal drug, HRS9432, for patients with candidemia (a yeast infection in the blood) or invasive candidiasis (yeast infection in organs). It aims to see if the drug is safe and works well for these serious infections.
Hear when a new Candida Auris Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.